Cover
Cover | 12 Months Ended |
Dec. 31, 2022 | |
Document Information [Line Items] | |
Document Type | DEF 14A |
Amendment Flag | false |
Entity Information [Line Items] | |
Entity Registrant Name | Corcept Therapeutics Incorporated |
Entity Central Index Key | 0001088856 |
Pay vs Performance Disclosure
Pay vs Performance Disclosure - USD ($) | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Pay vs Performance Disclosure [Table] | |||
Pay vs Performance [Table Text Block] | Year Summary Compensation Table Total for CEO Compensation Actually Paid to CEO Average Summary Compensation Table Total for Non-CEO Named Executive Officers (“NEOs”) Average Compensation Actually Paid to Non-CEO NEOs Value of Initial Fixed $100 Investment Based on: Net Income Revenue Total Shareholder Return Peer Group Total Shareholder Return 2022 $ 7,352,757 $ 9,573,427 $ 2,979,057 $ 3,906,349 $ 168 $ 123 $ 101,418 $ 401,858 2021 $ 10,984,638 $ 4,250,676 $ 5,343,525 $ 2,622,461 $ 164 $ 153 $ 112,512 $ 365,978 2020 $ 5,762,102 $ 13,607,297 $ 2,735,088 $ 6,189,352 $ 216 $ 121 $ 106,011 $ 353,874 | ||
Company Selected Measure Name | Revenue | ||
Named Executive Officers, Footnote [Text Block] | Dr. Belanoff was the CEO and President for each of 2022, 2021 and 2020.The non-CEO named executive officers reflects the following individuals in each year: | ||
Peer Group Issuers, Footnote [Text Block] | The Peer Group referenced for purpose of the Total Stockholder Return comparison consists of the Nasdaq US Benchmark TR Index. | ||
PEO Total Compensation Amount | $ 7,352,757 | $ 10,984,638 | $ 5,762,102 |
PEO Actually Paid Compensation Amount | $ 9,573,427 | 4,250,676 | 13,607,297 |
Adjustment To PEO Compensation, Footnote [Text Block] | SEC rules require certain adjustments be made to the Summary Compensation Table totals to determine Compensation Actually Paid as reported in the Pay versus Performance Table. Compensation Actually Paid does not necessarily represent cash and/or equity value transferred to the applicable named executive officer without restriction, but rather is a value calculated under applicable SEC rules. In general, Compensation Actually Paid is calculated as Summary Compensation Table total compensation adjusted to include the fair market value of equity awards as of December 31 of the applicable year or, if earlier, the vesting date (rather than the grant date). Named executive officers do not participate in a defined benefit plan so no adjustment for pension benefits is included in the table below. Similarly, no adjustment is made for dividends as dividends are factored into the fair value of the award. The following table outlines the adjustments made to the compensation earned by our CEO and non-CEO NEOs, as presented in the Summary Compensation Table, to derive the Compensation Actually Paid to our CEO and non-CEO NEOs. Item and Value Added (Deducted) 2022 2021 2020 For CEO: Summary Compensation Table Total $ 7,352,757 $ 10,984,638 $ 5,762,102 - Summary Compensation Table “Option Awards” column value (5,536,424) (9,290,888) (4,237,643) + year-end fair value of outstanding and unvested equity awards granted in the fiscal year 4,812,726 4,463,817 6,532,652 +/- change in fair value of outstanding and unvested equity awards granted in prior years 384,719 (2,243,056) 3,713,993 + vest date fair value of equity awards granted in the covered year 1,539,784 1,337,023 1,036,875 +/- change in fair value of prior-year equity awards vested in the fiscal year 1,019,865 (1,000,858) 799,318 Compensation Actually Paid $ 9,573,427 $ 4,250,676 $ 13,607,297 For Non-CEO NEOs (Average): Summary Compensation Table Total $ 2,979,057 $ 5,343,525 $ 2,735,088 - Summary Compensation Table “Option Awards” column value (2,100,777) (4,550,473) (1,995,790) - Summary Compensation Table “Stock Awards” column value (17,699) — — + year-end fair value of outstanding and unvested equity awards granted in the fiscal year 1,824,946 2,558,473 3,072,071 +/- change in fair value of outstanding and unvested equity awards granted in prior years 183,637 (821,551) 1,680,311 + vest date fair value of equity awards granted in the covered year 569,394 424,525 462,731 +/- change in fair value of prior-year equity awards vested in the fiscal year 467,791 (332,038) 234,941 Compensation Actually Paid $ 3,906,349 $ 2,622,461 $ 6,189,352 | ||
Non-PEO NEO Average Total Compensation Amount | $ 2,979,057 | 5,343,525 | 2,735,088 |
Non-PEO NEO Average Compensation Actually Paid Amount | $ 3,906,349 | 2,622,461 | 6,189,352 |
Adjustment to Non-PEO NEO Compensation Footnote [Text Block] | SEC rules require certain adjustments be made to the Summary Compensation Table totals to determine Compensation Actually Paid as reported in the Pay versus Performance Table. Compensation Actually Paid does not necessarily represent cash and/or equity value transferred to the applicable named executive officer without restriction, but rather is a value calculated under applicable SEC rules. In general, Compensation Actually Paid is calculated as Summary Compensation Table total compensation adjusted to include the fair market value of equity awards as of December 31 of the applicable year or, if earlier, the vesting date (rather than the grant date). Named executive officers do not participate in a defined benefit plan so no adjustment for pension benefits is included in the table below. Similarly, no adjustment is made for dividends as dividends are factored into the fair value of the award. The following table outlines the adjustments made to the compensation earned by our CEO and non-CEO NEOs, as presented in the Summary Compensation Table, to derive the Compensation Actually Paid to our CEO and non-CEO NEOs. Item and Value Added (Deducted) 2022 2021 2020 For CEO: Summary Compensation Table Total $ 7,352,757 $ 10,984,638 $ 5,762,102 - Summary Compensation Table “Option Awards” column value (5,536,424) (9,290,888) (4,237,643) + year-end fair value of outstanding and unvested equity awards granted in the fiscal year 4,812,726 4,463,817 6,532,652 +/- change in fair value of outstanding and unvested equity awards granted in prior years 384,719 (2,243,056) 3,713,993 + vest date fair value of equity awards granted in the covered year 1,539,784 1,337,023 1,036,875 +/- change in fair value of prior-year equity awards vested in the fiscal year 1,019,865 (1,000,858) 799,318 Compensation Actually Paid $ 9,573,427 $ 4,250,676 $ 13,607,297 For Non-CEO NEOs (Average): Summary Compensation Table Total $ 2,979,057 $ 5,343,525 $ 2,735,088 - Summary Compensation Table “Option Awards” column value (2,100,777) (4,550,473) (1,995,790) - Summary Compensation Table “Stock Awards” column value (17,699) — — + year-end fair value of outstanding and unvested equity awards granted in the fiscal year 1,824,946 2,558,473 3,072,071 +/- change in fair value of outstanding and unvested equity awards granted in prior years 183,637 (821,551) 1,680,311 + vest date fair value of equity awards granted in the covered year 569,394 424,525 462,731 +/- change in fair value of prior-year equity awards vested in the fiscal year 467,791 (332,038) 234,941 Compensation Actually Paid $ 3,906,349 $ 2,622,461 $ 6,189,352 | ||
Tabular List [Table Text Block] | Most Important Performance Measures Revenue Expand our commercial business serving patients with Cushing’s syndrome and continue to advance relacorilant as a potentially superior successor to Korlym Advance our proprietary selective cortisol modulators as potential treatments for patients with solid tumors, metabolic disorders and ALS Advance towards the clinic additional selective cortisol modulators and identify serious disorders for which they might fill an unmet medical need | ||
Total Shareholder Return Amount | $ 168 | 164 | 216 |
Peer Group Total Shareholder Return Amount | 123 | 153 | 121 |
Net Income (Loss) | $ 101,418,000 | $ 112,512,000 | $ 106,011,000 |
Company Selected Measure Amount | 401,858,000 | 365,978,000 | 353,874,000 |
PEO Name | Dr. Belanoff | Dr. Belanoff | Dr. Belanoff |
Additional 402(v) Disclosure [Text Block] | Total Stockholder Return is determined based on the value of an initial fixed investment of $100 at December 31, 2019. | ||
Measure [Axis]: 1 | |||
Pay vs Performance Disclosure [Table] | |||
Measure Name | Revenue | ||
Measure [Axis]: 2 | |||
Pay vs Performance Disclosure [Table] | |||
Measure Name | Expand our commercial business serving patients with Cushing’s syndrome and continue to advance relacorilant as a potentially superior successor to Korlym | ||
Measure [Axis]: 3 | |||
Pay vs Performance Disclosure [Table] | |||
Measure Name | Advance our proprietary selective cortisol modulators as potential treatments for patients with solid tumors, metabolic disorders and ALS | ||
Measure [Axis]: 4 | |||
Pay vs Performance Disclosure [Table] | |||
Measure Name | Advance towards the clinic additional selective cortisol modulators and identify serious disorders for which they might fill an unmet medical need | ||
PEO [Member] | Adjustment, Exclusion of Option Awards [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | $ (5,536,424) | $ (9,290,888) | $ (4,237,643) |
PEO [Member] | Equity Awards Granted During the Year, Outstanding and Unvested [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | 4,812,726 | 4,463,817 | 6,532,652 |
PEO [Member] | Equity Awards Granted in Prior Years, Outstanding and Unvested [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | 384,719 | (2,243,056) | 3,713,993 |
PEO [Member] | Equity Awards Granted in Covered Year [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | 1,539,784 | 1,337,023 | 1,036,875 |
PEO [Member] | Equity Awards Granted in Prior Years, Vested [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | 1,019,865 | (1,000,858) | 799,318 |
Non-PEO NEO [Member] | Adjustment, Exclusion of Option Awards [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | (2,100,777) | (4,550,473) | (1,995,790) |
Non-PEO NEO [Member] | Equity Awards Granted During the Year, Outstanding and Unvested [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | 1,824,946 | 2,558,473 | 3,072,071 |
Non-PEO NEO [Member] | Equity Awards Granted in Prior Years, Outstanding and Unvested [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | 183,637 | (821,551) | 1,680,311 |
Non-PEO NEO [Member] | Equity Awards Granted in Covered Year [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | 569,394 | 424,525 | 462,731 |
Non-PEO NEO [Member] | Equity Awards Granted in Prior Years, Vested [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | 467,791 | (332,038) | 234,941 |
Non-PEO NEO [Member] | Adjustment, Exclusion of Stock Awards [Member] | |||
Pay vs Performance Disclosure [Table] | |||
Adjustment to Compensation Amount | $ (17,699) | $ 0 | $ 0 |